




(86) Date de dépôt PCT/PCT Filing Date: 2003/11/19
(87) Date publication PCT/PCT Publication Date: 2004/06/03
(45) Date de délivrance/Issue Date: 2012/02/07
(85) Entrée phase nationale/National Entry: 2005/05/18
(86) N° demande PCT/PCT Application No.: EP 2003/012955
(87) N° publication PCT/PCT Publication No.: 2004/045582
(30) Priorité/Priority: 2002/11/21 (US60/428,435)

(51) Cl.Int./Int.Cl. *A61K 9/127* (2006.01)
(72) Inventeurs/Inventors:
BRUNNER, JOSEF, CH;
VADRUCCI, SONJA, CH;
ZURBRIGGEN, RINALDO, CH
(73) Propriétaire/Owner:
PEVION BIOTECH LTD., CH
(74) Agent: BLAKE, CASSELS & GRAYDON LLP

(54) Titre : VESICULES FUSOGENES HAUTEMENT EFFICACES, LEURS PROCEDES DE PRODUCTION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT

(54) Title: HIGH-EFFICIENCY FUSOGENIC VESICLES, METHODS OF PRODUCING THEM, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM



(57) Abrégé/Abstract:

The present invention relates to novel fusogenic vesicles as highly efficient and versatile encapsulation systems for delivering a substance of choice, such as nucleic acids, proteins, peptides, antigens, pharmaceutical drugs and cosmeceuticals to cells and tissues.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
3 June 2004 (03.06.2004)

PCT

(10) International Publication Number
WO 2004/045582 A1

(51) International Patent Classification⁷: **A61K 9/127**

(21) International Application Number:
PCT/EP2003/012955

(22) International Filing Date:
19 November 2003 (19.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/428,435 21 November 2002 (21.11.2002) US

(71) Applicant (for all designated States except US): **PEVION BIOTECH LTD.** [CH/CH]; Rehhagstrasse 79, CH-3018 Bern (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BRUNNER, Josef** [CH/CH]; Baslerstrasse 47, CH-4600 Olten (CH). **VADRUCI, Sonja** [IT/CH]; Schneckenmannstrasse 9, CH-8044 Zürich (CH). **ZURBRIGGEN, Rinaldo** [CH/CH]; Rainstrasse 40, CH-3185 Schmittlen (CH).

(74) Agent: **NOBBE, Matthias**; Vierung, Jentschura & Partner, Centroallee 263, 46047 Oberhausen (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HIGH-EFFICIENCY FUSOGENIC VESICLES, METHODS OF PRODUCING THEM, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM



(57) Abstract: The present invention relates to novel fusogenic vesicles as highly efficient and versatile encapsulation systems for delivering a substance of choice, such as nucleic acids, proteins, peptides, antigens, pharmaceutical drugs and cosmeceuticals to cells and tissues.

WO 2004/045582 A1

**HIGH-EFFICIENCY FUSOGENIC VESICLES, METHODS OF PRODUCING
THEM, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM**

The present invention relates to novel fusogenic vesicles as
5 highly efficient and versatile encapsulation systems for
delivering a substance of choice, such as nucleic acids,
proteins, peptides, antigens, pharmaceutical drugs and
cosmetical agents to cells and tissues.

10 One of the paramount goals of medical therapy is the
efficient delivery of therapeutic substances to the site of
disease. While some therapeutic substances can be delivered
in free form, others require a carrier or vector in order to
reach and enter their final destination, either due to their
15 rapid clearance from the area of introduction or their
inability to cross biological barriers, or due to their
systemic toxicity. Delivery of substances to cells and
tissues requires vectors which are efficient, flexible, easy
to prepare and safe. Currently available methods for
20 delivering substances to eukaryotic cells involve the use of
either viral or non-viral vectors. Viral vectors are
replication-defective viruses with part of their coding
sequences replaced by that of a therapeutic gene. Although
recombinant viruses are highly efficient gene delivery and
25 expression vectors, they are currently limited to the
delivery of nucleic acids and their safety profiles have not
yet been established for medical use in humans.

Most non-viral delivery systems operate at the following
30 levels: loading of the delivery vector with a substance of
interest (e.g. proteins, peptides, nucleic acids,
pharmaceutical or other therapeutic drugs), endocytosis, and
in the case of gene delivery, nuclear targeting and entry.
The major drawback of non-viral systems, such as liposomes,

CONFIRMATION COPY

is their low delivery efficiency to cells (Chu *et al.*, *id.*; Legendre and Szoka, 1992, Pharmaceut. Res. Vol.9, P.1235), presumably due to the absence of fusion-mediating molecules on the surface of the liposomes. A hybrid type of delivery system, the virosome, combines the efficient delivery mechanism of viruses with the versatility and safety of non-viral delivery systems. Virosomes are reconstituted envelopes without the infectious nucleocapsids and the genetic material that can be derived from a variety of viruses. These virosomes are functional, in that their membrane fusion activity closely mimics the well-defined low-pH-dependent membrane fusion activity of the intact virus, which is solely mediated by the viral fusion protein. Like viruses, virosomes are rapidly internalized by receptor-mediated endocytosis. In contrast to viral systems virosomes are safe, since the infectious nucleocapsid of the virus has been removed. Thus, virosomes represent a promising carrier system for the delivery of a wide variety of different substances, either encapsulated in their aqueous interior or co-reconstituted in their membranes. Co-reconstitution of different receptors within the virosomal membrane, furthermore, allows the targeting of virosomes to different cells or tissues. So far, virosomes are mainly used as vaccines by adding antigen onto the surface of the virosomes.

A major limitation of the protocol currently used to prepare virosomes is that it does not result in high encapsulation efficiency. At the lipid concentration at which virosomes are produced (~1 mM lipid), and given their mean diameter of approximately 200 nm, less than 1% of the aqueous phase will be entrapped within the virosomes (Schoen *et al.*, *J. Liposome Res.* 3: 767-792, 1993). Such low entrapment rates reduce virosome-mediated efficiency of drug or gene delivery to cells. The development of new/novel, more efficiently loaded vesicles that retain the advantageous fusion properties of

virosomes, as well as methods of making, loading, and delivering them would thus be a highly desirable goal in the field of therapeutic drug, protein and gene delivery.

5 One of the problems in current virosome technology is the lack of methods for the efficient entrapment of a solute, e.g. protein, nucleic acid, or pharmaceutical drug. The present invention provides a novel approach that circumvents the problems of low virosomal entrapment efficiencies.

10

Therefore the invention provides a fusogenic vesicle, composed of virosomal and liposomal lipids that is encapsulating at least one therapeutic or immunologically active substance whereby said fusogenic vesicle is comprising
15 fusion proteins, preferably at least two different fusion proteins or fragments thereof, said fragments having the fusion activity and characteristics of the complete fusion protein at least in an extent serving for the fusion with a biological membrane of the target cell, with distinct fusion
20 characteristics. Preferably, the vesicle is unilamellar. The vesicle has a diameter generally in the range of 100 to 600 nm, and preferably a diameter of between 100 nm and 300 nm or a diameter of between 200 nm and 400 nm, depending on the specific vesicle.

25

The invention takes advantage of the fact that liposomes, which can be prepared at very high lipid concentrations, have high encapsulation efficiencies. Thus, the invention provides a methodology that combines the high loading capacity of
30 liposomes with the efficient cell-fusion and delivery of virosomes, resulting in substantially increased entrapment of solutes, like proteins, nucleic acids, and pharmaceutical drugs, within functional chimeric virosomes of controlled size that are capable of efficiently delivering therapeutic
35 or immunologically active substances to cells.

Accordingly, in a preferred embodiment of the invention, the substance of interest is first loaded into, or encapsulated by, liposomes. The liposomal lipids which are used in the present invention are preferably selected from the group consisting of cationic lipids, synthetic lipids, glycolipids, phospholipids cholesterol or derivatives thereof.

Phospholipids comprise preferably phosphatidylcholine, sphingomyelin, phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, phosphatidic acid, cardiolipin and phosphatidylinositol with varying fatty acyl compositions. Cationic lipids are preferably selected from the group consisting of DOTMA (N-[(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride), DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride), DODAC (N,N-dioleoyl-N,N,-dimethylammonium chloride), DDAB (didodecyldimethylammonium bromide) and stearylamine or other aliphatic amines and the like. They are generally formulated as small unilamellar liposomes in a mixture with DOPE (dioleoylphosphatidyl ethanolamine) that is widely used as 'helper' lipid to facilitate disruption of the endosomal membrane. Most preferably the liposomal lipids of the liposomes comprise POPC/DDAB.

In a second step, liposomes containing the substance of interest will be fused with chimeric virosomes having different types of fusion proteins in their membranes. The term „fusion protein or fragments thereof“ refers to proteins or fragments thereof capable of inducing and/or promoting a fusion reaction between the fusogenic vesicle membrane and a biological membrane of the target cell.

After resizing, the products of the liposome-virosome fusion will be virosome-like particles, or proteoliposomes, that contain the substance of interest in their internal cavity

and are still capable of undergoing a second fusion step, under different conditions, with biological membranes in order to deliver the therapeutic or immunologically active substance.

5

The fusogenic vesicle of the present invention is encapsulating at least one substance, preferably a therapeutic or an immunologically active substance, that is preferably selected from the group consisting of DNA, RNA,
10 siRNA, proteins, peptides, amino acids and pharmaceutical active substances or derivatives thereof. Preferably the at least one substance is a cosmetical agent, a pharmaceutical drug, an antigen or a mixture thereof.

15 Examples for the cosmetical substance are selected from antipsoriatics and antifungals for dermatological use. Examples for the therapeutic substance or pharmaceutical drugs are selected from the group comprising anaesthetics, angiogenesis inhibitors, anti-acne preparations, anti-
20 allergics, antibiotics and chemotherapeutics for topical use, antihistamines, antiinflammatory/antiinfective, antineoplastic agents, antigens, antiprotozoals, antirheumatic, antiviral vaccines, antivirals, aptoptosis, bacterial vaccines, chemotherapeutics, cytostatics,
25 immunosuppressive agents, laxatives, psycholeptics.

Preferred examples for the cosmetical agent are tars nystatin and for the pharmaceutical drug the immunologically active substance doxorubicin, vinblastine, cisplatin, methotrexate,
30 ciclosporin, ibuprofen, HCV based T-cell antigens and tumor associated antigens.

Encapsulation of at least one therapeutic substances, such as proteins, peptides, nucleic acids, pharmaceutical,
35 chemotherapeutic or cosmetic drugs into liposomes can be

performed by any method known in the art, including the procedures described in Monnard *et al.*, *Biochim. Biophys. Acta* 1329: 39-50; 1997, in Wagner *et al.*, *J. Liposome Res.*, 12(3) 271-283, 2002, or in Oberholzer *et al.*, *Biochim.*

5 Biophys. *Acta* 1416: 57-68; 1999, among many other well-known methods. In a preferred embodiment of the invention, high liposomal encapsulation efficiencies are achieved by the freeze/thaw technique used to prepare pure lipid vesicles. With this method, approximately 50% of the initial amount of
10 a linearized plasmid over 3 kb can be entrapped within large unilamellar vesicles (LUVs) consisting preferably of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)/didodecyldimethylammonium bromide (DDAB) (Monnard *et al.*, *Biochim. Biophys. Acta* 1329: 39-50, 1997).

15

In one preferred embodiment, the invention provides for the preparation of virosomes containing a binary mixture of viral fusion molecules that display distinct fusion

characteristics. In another preferred embodiment of the
20 invention, different viral hemagglutinin (HA) fusion proteins are used to construct the chimeric virosomes. As shown previously (Tsurudome *et al.*, *J. Biol. Chem.* 267: 20225-20232, 1992), HA fusion proteins from different strains of viruses can display markedly different temperature

25 characteristics of fusion and inactivation. For example, about pH 5.0, X-31 HA triggers fusion efficiently at low temperature, whereas at the same pH, HA from PR8/34 or A/Singapore virus requires elevated temperature (>25°C).

Hence, in a preferred embodiment of the invention, the
30 chimeric virosomes contain proteins in their membrane that mediate fusion at two distinct temperatures. Different temperature-sensitivity is a particularly advantageous characteristic of the fusion proteins, as it allows convenient and simple control of fusion reactions. As an

example, the present invention demonstrates that virosomes containing HA molecules from both X-31 and PR8/34 virions are capable of catalyzing two distinct fusion reactions at pH 5: the first at low temperature (0-4-10°C), the second at
5 elevated temperature (>25 °C). However, other fusion proteins with distinct fusion characteristics, including sensitivity to temperature, ion concentration, acidity, cell type and tissue type specificity, etc. are well known in the art and may be used for the purposes of the present invention. Fusion
10 proteins with different fusion characteristics can be derived from different influenza strains, such as MRC-11, X-97, NIB24, NIB26, X-47, A/Johannesburg/33 and A/Singapore, to name a few. In addition, other known viral fusion proteins may be used, such as the vesicular stomatitis virus (VSV) G
15 protein, the Semliki forest virus (SFV) E1 protein, or the Sendai virus F protein, among many others, to construct chimeric virosomes capable of undergoing sequential and separate fusion events. Furthermore, the chimeric virosomes and resulting virosome-like proteoliposomes loaded with the
20 therapeutic substance of interest may contain fusion proteins that target the virosome-like proteoliposomes to specific cells or tissues. Thus, for instance, fusion proteins that are specific for certain cell surface receptors, such as the gp41/gp120 protein of HIV (gp120 binds to CD4 on CD4⁺ T
25 lymphocytes and cells of the monocyte/macrophage lineage) can be used to target delivery of therapeutic substances to specific cell types or tissues. Other such cell- or tissue-specific fusion proteins are well known in the art and can be conveniently incorporated into the vesicles of the present
30 invention.

In addition to the fusion proteins, the fusogenic vesicle of the present invention can further have, incorporated in the membrane or attached thereto, a cell-surface receptor, a
35 cytokine, a growth-factor, an antibody or an antibody

fragment to improve targeting of the fusogenic vesicle to different cells or tissues.

As shown by the present invention, once such chimeric
5 virosomes are constructed, they can be fused at a first specified condition to trigger fusion of the first viral fusion protein or peptide with liposomes containing the encapsulated substance or substances of interest, such as proteins, peptides, nucleic acids, or pharmaceutical drugs.

10 The invention demonstrates for the first time that the fusion of chimeric virosomes with substance-loaded liposomes generates virosome-like proteoliposomes which not only encapsulate the substance of interest, but are still capable of mediating an additional fusion event under different
15 conditions, for example, under different conditions for temperature, ion concentration etc. After proper manipulation to control their size, these substance-containing proteoliposomes can be delivered to cells where they are efficiently taken up. In the environment of the endosome, the
20 second fusion molecules can trigger a second fusion reaction between the virosomal and endosomal membranes. As illustrated in Fig. 1 this multi-step process results in the transfer of liposome-encapsulated substances into the cytosolic compartment of cells.

25

Procedures for the preparation of virosomes (also referred to in this application as immunopotentiating reconstituted influenza virosomes (IRIV)) are well known to those of skill in the art (Bron *et al.*, Methods Enzymol. 220: 313-331,
30 1993). Influenza virosomes, for example, can be reconstituted from the original viral membrane lipids and spike glycoproteins after solubilization of intact influenza virus with octaethyleneglycol monododecyl ether, sedimentation of the nucleocapsid (the viral glycoproteins and lipids will
35 remain in the supernatant), and removal of the detergent in

the supernatant with a hydrophobic resin (Bio-Beads^{*} SM2) (Stegmann et al., Traffic 1: 598-604, 1987). For the preparation of chimeric virosomes containing HAs from X-31 and PR8/34 strains of viruses, as one example, equal amounts
5 of protein of both viruses were solubilized with the non-ionic detergent C₁₂E₈. Isolation of other viral fusion proteins is a matter of routine to those of skill in the art. After removal of the detergent with Bio-Beads^{*} SM2, new envelopes containing both types of fusion proteins were
10 formed. SDS-PAGE of exemplary chimeric virosomes containing two different types of HA fusion proteins showed (Fig. 2) that very similar amounts of the fusion proteins, here PR8 and X-31 HA, are reconstituted into chimeric virosomes. The HA/phospholipid ratio is approximately 1.4 mg/μmol.

15 To determine their morphology, the chimeric virosomes constructed can be characterized by cryo-TEM. The reconstituted particles were unilamellar vesicles with a diameter ranging between 150-250 nm; some smaller vesicles
20 were also visible (Fig. 3). The density of hemagglutinin spikes was clearly lower than that typically seen in intact virus particles. This is consistent with the measured HA/phospholipid ratio of 1.4 mg/μmol for chimeric virosomes, which is somewhat lower than that of intact virions
25 (approximately 2 mg/μmol). Furthermore, HA-spikes are present on both sides of the membrane at about equal density.

The fusion properties of chimeric virosomes with liposomes, such as the dependence of fusion activity on a certain
30 temperature, pH, or other parameter, *in vitro* can be determined using the lipid mixing assay (Struck et al., Biochemistry 20: 4093-4099, 1981). This assay is based on fluorescence resonance energy transfer (FRET) and makes use of the two fluorophores N-NBD-PE (energy-donor) and N-Rh-PE
35 (energy-acceptor) present within one of the two membranes

* - Trademark

(e.g. liposomes). A variant of this assay, utilizing the same donor N-NBD-PE but a different acceptor, cholesterol-anthracene-9-carboxylate (CAC), may also be used. Another variant of this assay, utilizing the same acceptor N-Rh-PE but a different donor, Bodipy 530/550-DHPE, may also be used. Upon fusion the two fluorophores move apart and the fluorescence emitted by the donor increases (or that of the acceptor decreases). As an example, the fusion activity of X-31/PR8/34 chimeric virosomes was compared with that of X-31 and PR8/34 virus as well as with the corresponding virosomes (Fig. 4). As target membranes, unilamellar liposomes prepared from POPC/POPG (4:1) and the two fluorophores (0.6% each) were used. As shown in Fig. 4.1a, both X-31 virus and X-31 virosomes fused efficiently with the liposomes at 4°C and pH 5.0. Because the X-31 and PR8/34 HA fusion proteins both require an acidic pH, no fusion occurred at neutral pH. Preincubation of X-31-HA at low temperature and low pH almost completely abolished its fusion-activity (Fig. 4.1b).

By contrast, at 4°C, pH 5.0, PR8/34 virus and virosomes neither fused nor, importantly, underwent inactivation (Fig. 4.2a). However, they were able to trigger fusion at 37°C (Fig. 4.2b). According to these data, chimeric virosomes can be designed to perform two distinct fusion reactions, depending on the parameters for which each fusion protein is specific. For example, the PR8/34/X-31 chimeric virosomes can perform one fusion reaction at low temperature (4°C; Fig. 4.3a) and a second fusion reaction at higher temperature (37°C; Fig. 4.3b). A surprising and important discovery of the present invention is that the preincubation of chimeric virosomes with target membranes at low temperature and low pH does not eliminate fusion-activity at elevated temperature (Fig. 4.3b). Therefore, the present invention provides for a controlled fusion reaction that results in the formation of

loaded virosomes capable of fusing again under different conditions.

The fact that the prepared liposomes are unilamellar is of great importance for the subsequent fusion step with chimeric virosomes, since the loaded substance should be released into the internal cavity of the newly formed vesicle rather than remaining trapped between membrane layers. To examine a possible interaction of the loaded substance with the lipids used and its effect on the liposome morphology, plasmid-containing vesicles were subjected to cryo-TEM. The electron micrographs in Fig. 6 show that the cationic vesicles were unilamellar and 100-150 nm in size. In contrast to other preparations containing cationic lipids and DNA, where multilamellar, tubular structures are formed (Gershon *et al.*, Biochemistry 32: 7143-7151, 1993), advantageously in this procedure homogeneous unilamellar vesicles are generated.

To demonstrate the feasibility of the approach, the encapsulation efficiency of the therapeutic or immunologically active substance of choice, in this case the 6.5 kb model plasmid, was determined. As determined after digestion of free plasmid-DNA with DNase I/Exonuclease III, digestion and separation by gel filtration the entrapment efficiency achieved was approximately 40% of a circular, 6.5 kb model plasmid. Quantitation of the remaining intact DNA can either be based on radioisotopic labeling of the DNA, or visual comparison with standard amounts on an agarose gel following staining with ethidiumbromide, as described in Fig. 5. To ascertain that accessible DNA was degraded quantitatively, control experiments were performed in which all DNA was accessible (i.e. liposomes solubilized with a detergent (Fig. 5, lanes 9 and 10) or DNA on the outside (Fig. 5, lanes 11 and 12)). These results thus demonstrate that the DNase I/Exonuclease III-resistant fraction is

effectively entrapped in the internal cavity of the liposomes, and not just inaccessible to DNase I and Exonuclease III because of (protective) interactions with the cationic lipid. The entrapment achieved (35-40%) is quite
5 significant, thus making this approach suitable for therapeutic applications.

Following the successful preparation of the chimeric virosomes and the unilamellar liposomes loaded with the
10 substance of interest, the present invention provides for the fusion of these two vesicular systems. However, there are several major obstacles that had to be overcome before the desired fusogenic and loaded virosomes were obtained. Because virosomes are capable of fusing both with liposomes and other
15 virosomes, as well as with the primary products of fusion, multiple rounds of fusion were shown to occur in the mixture of loaded liposomes with chimeric virosomes. These uncontrolled fusion events resulted in a significant percentage of large, undefined structures. Such large
20 structures are unsuitable for the delivery of therapeutic substances to cells, as their endocytosis by cells is expected to be severely compromised. Furthermore, the multiple rounds of fusion resulted in populations of virosome-like end products (proteoliposomes) with a wide
25 variety of different sizes. Such heterogeneously sized populations are therapeutically undesirable because the amount and dosage of the encapsulated therapeutic substance cannot be controlled. In addition, encapsulation of the original liposome-entrapped therapeutic or immunologically
30 active substance of interest within an internal compartment of the resulting chimeric virosome-like proteoliposomes has not previously been demonstrated. It was doubtful whether successful encapsulation would be achieved or whether fusion would result in partial or total release of the therapeutic
35 substance of interest. Lastly, it was uncertain whether the

fused vesicles would retain fusion capacity under the second set of conditions or parameters, such as elevated temperature.

5 To investigate the products of the fusion between liposomes and virosomes containing different fusion proteins, samples of fused vesicles were characterized by cryo-transmission electron microscopy (cryo-TEM). The liposome-virosome fusion products showed vesicles with a size distribution between 450
10 nm and 900 nm (Fig. 7, upper panels). Some smaller vesicles, possibly original virosomes, were detected (Fig. 7, top left). On the other hand, it appeared that all of the liposomes underwent at least one round of fusion. The presence of very large vesicles (> 900 nm) is evidence that
15 multiple rounds of fusion take place in the virosome-liposome fusion step. In order to solve the problem of uncontrollable fusion and to generate homogeneously sized vesicles that would allow control over drug or substance delivery dosage, the vesicles would have to be manipulated so as to generate
20 vesicles of uniform size. Ideally, the large diameter vesicles that are unsuitable for endocytosis would have to be reduced in size without causing loss of the encapsulated contents or fusogenicity. Therefore, the present invention further comprises re-sizing the fusogenic vesicles obtained
25 after fusing liposomes encapsulating at least one therapeutic or immunologically active substance with virosomes having fusion proteins with distinct fusion characteristics. In accordance with the invention, said resizing can be carried out by extrusion of the vesicles.

30

Accordingly, the present invention provides for a size-reduction step of the virosome-like proteosomes obtained through the fusion of chimeric virosomes with loaded liposomes, which remarkably causes neither loss of the
35 encapsulated substance from the vesicles nor inactivation of

the remaining functional fusion protein with concomitant loss of fusogenicity. Thus, in a preferred embodiment of the invention, the reaction products of the virosome-liposome fusion reaction are subjected to a nucleopore extrusion step in order to reduce their size. As shown in Fig. 7, lower panels, extrusion through 200 nm pores yields vesicles of approximately half of the original size as shown by cryo-TEM. Most particles are between 100-300 nm, rarely also larger vesicles (500-600 nm) can be detected. The fact that the extrusion step results in re-sized fusogenic virosome-like vesicles without significant loss of encapsulated substance is a rather unexpected and highly advantageous result, as the shearing forces applied during extrusion would be expected to rupture the majority of the membranes, causing loss of entrapped material and inactivation of the fusion proteins. That the extrusion step leads neither to any significant loss of the entrapped plasmid-DNA nor inactivation of the second fusion protein (the PR8-hemagglutinin), was verified by testing the fusogenicity and the DNA-content of extruded proteoliposomes. FRET-measurements showed that the fusogenicity of the loaded proteoliposomes before and after extrusion was the same (Fig. 8). Further, the plasmid content of the extruded proteoliposomes was determined. Toward this end, liposomes containing radioactive plasmid DNA were prepared (free DNA was digested with DNase and nucleotides were removed by gel filtration; entrapped DNA = 100%). Subsequently, these liposomes were subjected to fusion with virosomes. One aliquot of the fusion products was treated directly with DNase I, the other following extrusion through nucleopore membranes. After removal of the free nucleotides, the radioactivity entrapped within the proteoliposomes was determined. From the results it can be concluded that during the initial fusion step, no more than 15 % (± 5 % s.d.; n=2) and during both the fusion and extrusion step, no more than 25 % (± 3 % s.d.; n=2) of the originally entrapped DNA is

lost. Thus, the amount of radioactivity found in
proteoliposomes after extrusion is only slightly lower than
before extrusion. That the liposome-virosome fusion retains
most of the entrapped substance is even more surprising when
5 one considers the reports that HA-mediated membrane fusion is
a leaky process (Shangguan et al., Biochemistry 35: 4956-
4965, 1996).

Thus, the present invention provides a procedure for the
10 preparation of fusion-competent proteoliposome vesicles that
efficiently encapsulate a substance of interest for delivery
to cells and tissues. The cellular uptake of these novel
proteoliposome vesicles can be traced by the fluorescent
lipid rhodamine phosphatidylethanolamine (Rh-PE) stably
15 inserted within the membrane bilayer. The labeled
proteoliposomes were added to MDCK or HeLa-cells (approx.
 1×10^5 cells) cultured on coverslips in 24-well plates.
Following incubation at 4°C for 1 h to allow binding to
cells, unbound particles were removed and cells were
20 incubated for an additional 15 min at 37°C. After fixation
with formaldehyde cells were analyzed by fluorescence
microscopy.

After this (short) incubation at 37°C, a clear punctate,
25 perinuclear staining was visible (Fig. 9 B), indicating that
rhodamine-labeled proteoliposomes had been rapidly
internalized. This process was temperature dependent since at
4°C all particles remained at the cell surface (Fig. 9 A).
Furthermore, it was also dependent on the fusion protein in
30 the vesicle membrane, as protein-free Rh liposomes were not
internalized to a detectable extent within 2 hours. These
results show that chimeric proteoliposomes are rapidly
internalized; in all likelihood by receptor-mediated
endocytosis, as is the case for influenza virus. Likewise,
35 dextran can be added to liposomes at a high concentration and

because of its smaller size it is assumed that several labeled molecules can be incorporated into one proteoliposome. In fact, theoretically, at the concentration of dextran used (37.5 mg/ml) approximately 170 dextran molecules can be incorporated into one liposome. With the degree of substitution being six fluorophores per dextran molecule, one thousand Texas-red molecules should be available per liposome. It was expected that if the encapsulated material is released into the cytosol a diffuse, cytosolic staining should be visible by fluorescence microscopy versus a punctate perinuclear staining if the substance remains entrapped. Dextran was entrapped into POPC/DDAB-liposomes as described in the examples. Liposomes were fused with chimeric virosomes and the fusion products added to cells cultured on coverslips. Cells were incubated for 1 h at 4°C, then unbound material was washed away and cells were incubated for different time at 37°C. After fixation with 3.7% (v/v) formaldehyde, cells were analyzed by fluorescence microscopy. Uptake of dextran-proteoliposomes could be detected after a 15 minute incubation at 37°C, as already seen for rhodamine-labeled proteoliposomes. At this stage a substantial amount of dye was at the cell surface (Fig. 10 B). Later (Fig. 10 C and D) a more perinuclear staining could be observed.

25

To further demonstrate the feasibility of the approach, the encapsulation efficiencies of other therapeutic substances of choice were determined. Hydrophobic as well as hydrophilic peptides, proteins (e.g. recombinant green fluorescent protein, GFP) and small molecules (e.g. PicoGreen) were used. Table 1 represents a summary of these results. With the conventional preparation procedure (Schoen et al., J. Liposome Res. 3: 767-792, 1993) encapsulation efficiencies below 5% were obtained. However, the new approach resulted in

30

encapsulation efficiencies at least above 15% in every case (Table 1).

Table 1

5

Encapsulation efficiencies of different molecules at subsequent steps during IRIV preparation

Encapsulated molecule	Liposomes (0.2 μ m diameter) ¹	"Fused" IRIV ² (Proteoliposomes)	"Conventional" IRIV ³
Hydrophilic peptides	> 20%	> 18%	0.1-0.5%
Hydrophobic peptides	> 15%	> 15%	0.1-2.0%
GFP ⁴	> 15%	> 15%	0.1-0.5%
PicoGreen ⁵	> 30%	> 25%	0.5-4.5%
Plasmid DNA	> 30%	> 25%	0.1-1.0%

10 ^{1,2} Preparation of liposomes and liposomes fused with IRIV (proteoliposomes) is described in detail in Example 6

³ Preparation of "conventional" IRIV is described in Example 3

⁴ GFP: green fluorescent protein

⁵ PicoGreen: DNA intercalator

15

Thus, the present invention provides for improved, virosome-based carrier systems for the delivery of therapeutic substances, including macromolecules, to cells. Because of their safety profile (when compared to viral vectors) and
 20 their rapid cellular uptake the virosome-like fusogenic proteoliposomes of the instant invention represent a promising system that can also be used for the preparation of a pharmaceutical formulation for the treatment or prevention of viral, bacterial and fungal infections, degenerative
 25 diseases, hyper-proliferative diseases and other kinase

associated disorders including cancer, infectious diseases, chronic infectious diseases, chronic diseases, allergies, cardiovascular diseases, inflammatory diseases (including skin inflammatory diseases such as psoriasis), immune
5 diseases, cancer immune disorders, asthma or arthritis.

A further advantage of the vesicles presented here is their potential targeting to specific cells or tissues by co-reconstituting receptors, antibodies, or antibody fragments
10 (Mastrobattista *et al.*, FEBS Lett. 509: 71-76, 2001) within the vesicle membrane. In addition, because virosomes have been shown to work as excellent adjuvants (Glück, Vaccine 17: 1782-1787, 1999), the virosome-like proteoliposomes of the present invention can be adapted for use in vaccination, in
15 addition to drug delivery. By providing efficient encapsulation of substances, including macromolecules, the present invention fulfills an urgent need in the art. The 25-30% entrapment efficiencies shown here of a model plasmid within closed, unilamellar fusogenic proteoliposomes far
20 exceed those of previously used techniques in which entrapment efficiencies below 1% were measured (Schoen *et al.*, J. Liposome Res. 3: 767-792, 1993). In addition, the prepared exemplary proteoliposomes were found to undergo efficient fusion with model membranes at low pH and elevated
25 temperature. Internalization by cells in culture (HeLa, MDCK) was rapid and in the same range as for virus and virosomes (Bron *et al.*, Biochemistry 33: 9110-9117, 1994; Nunes-Correia *et al.*, Biochemistry 38: 1095-1101, 1999).

30 The following examples are provided to better illustrate the claimed invention and are not to be interpreted as limiting the scope of the invention. To the extent that specific materials are mentioned, it is merely for purposes of illustration and is not intended to limit the invention. One

skilled in the art may develop equivalent means or reactants without the exercise of inventive capacity and without departing from the scope of the invention.

5 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1: This figure shows the simplified scheme representing the overall strategy of the invention. In a first fusion step, chimeric virosomes are fused at 4°C (pH 10 5.0) with liposomes containing the substance to be delivered, (in this example DNA) mediated by X-31 HA. Subsequently, the resulting neutralized fusion products are incubated with cells. After receptor-mediated endocytosis, the virosome-like proteoliposomes now containing the substance to be delivered 15 undergo a second round of fusion, triggered by the low pH within endosomes and mediated by PR8/34 HA, releasing the entrapped substance into the cytosol.

Figure 2: This figure shows the presence of both types of 20 fusion proteins in the membrane of the chimeric virosomes. SDS-PAGE of X-31 and PR8 virus and virosomes. Approx. 10 µg virus and 3 µg virosomes were loaded under non-reducing conditions on a SDS-Tris/Tricine 10% (v/v) polyacrylamide gel (Schägger et al., Anal. Biochem. 166: 368-379, 1987). The 25 polyacrylamide gel was stained with Coomassie blue. Lane 1: X-31 virus. Lane 2: X-31 virosomes. Lane 3: chimeric virosomes. Lane 4: PR8 virosomes. Lane 5: PR8 virus.

Figure 3: This figure shows the morphology of the chimeric 30 virosomes by cryo-TEM. They are unilamellar vesicles with diameters ranging from 150 - 250 nm. Scale bar 100 nm.

Figure 4: This figure shows the fusion activity of X-31, PR8 viruses, virosomes and X-31/PR8 chimeric virosomes with

liposomes. Fluorescence was recorded continuously at excitation and emission wavelengths of 465 nm and 530 nm, respectively. Measurements were carried out with a SPEX-Fluorolog-2 fluorometer (SPEX Industries, Inc., Edison, NJ, USA) equipped with a thermostated cuvette holder and a magnetic stirring device. For calibration of the fluorescence scale the initial residual fluorescence of the liposomes was set to zero and the fluorescence at infinite probe dilution to 100%. The latter value was determined by addition of Triton X-100 (0.5% v/v). 1) X-31 virus and virosomes fused with POPC/POPG-LUVs. 2) PR8/34 virus and virosomes incubated with POPC/POPG-LUVs. 3) Chimeric virosomes incubated with POPC/POPG-LUVs. a) fusion measurements at 4°C; b) Virus and virosomes were incubated at 4°C and pH 5.0 for 1 h with POPC/DDAB-LUVs before fusion measurements at 37°C.

Figure 5: This figure shows the encapsulation efficiency of DNA into POPC/DDAB-liposomes. DNA-containing liposomes were prepared by the freeze/thaw method as described in the examples and digested for 3 h at 37°C with DNase I/Exonuclease III. After that, encapsulated DNA was phenol/chloroform extracted and subjected to gel electrophoresis on a 1% agarose gel. In lane M 1 Kb plus Ladder marker was loaded. As control 100 ng (lane 1) and 200 ng plasmid-DNA (lane 2) were directly loaded on the gel. As another control untreated (not DNase I digested) DNA-liposomes corresponding to 20 ng (lane 3), 50 ng (lane 4), 100 ng (lane 5) and 200 ng (lane 6) plasmid were phenol/chloroform extracted. The aqueous phase was loaded on the gel. DNase I digested liposomes corresponding to an initial DNA-amount of 50 ng (lane 7) and 100 ng (lane 8) were treated like the samples before. Lane 9 and 10 correspond to the same amount of liposomes, except that liposomes had been solubilized with 1% (v/v) Triton X-100 before DNase I

treatment. In lane 11 and 12 DNA was not encapsulated, but added to empty liposomes. Also these liposomes were treated as described above.

5 **Figure 6:** This figure shows the morphology of loaded liposomes by cryo-TEM of. They are unilamellar and measure between 100-150 nm in diameter. Scale bar 100 nm.

Figure 7: This figure shows the products of the fusion
10 between the chimeric virosomes and the loaded liposomes by cryo-TEM before (upper panels) and after extrusion (lower panels). Before extrusion, the vesicles are of widely varying sizes with some vesicles exceeding 900 nm. This result indicates multiple rounds of fusion. Scale bars upper panels:
15 500 nm; scale bars lower panels: left: 100 nm; right: 200 nm.

Figure 8: This figure demonstrates the fusogenicity of the extruded vesicles resulting from the fusion of chimeric virosomes with liposomes. Remarkably, the vesicles retain
20 their fusion activity. The proteoliposomes were extruded through nucleopore membranes. Fluorescence was recorded continuously at excitation and emission wavelengths of 465 nm and 530 nm, respectively. Measurements were carried out with a SPEX-Fluorolog-2 fluorometer equipped with a thermostated
25 cuvette holder and a magnetic stirring device. 100% corresponded to infinite probe dilution, determined after addition of Triton X-100 (0.5% v/v). Fusion measurements were carried out at 37°C and pH 5.0 with POPC/POPG (4:1)-LUVs containing 0.6% N-NBD-PE and N-Rh-PE.

30

Figure 9: This figure shows that the proteoliposomes are rapidly internalized by cells. Rhodamine-labeled proteoliposomes are detected in MDCK and HeLa cells. Fused virosomes were bound at 4°C for 1 h to HeLa and MDCK cells.

After that, unbound material was washed away. Cells were immediately fixed (A), or incubated for another 15 min at 37°C, fixed with 3.7% (v/v) formaldehyde and analyzed by fluorescence microscopy (B).

5

Figure 10: This figure shows the rapid uptake of proteoliposomes loaded with Texas Red dextran by HeLa cells. HeLa cells were incubated with Texas Red dextran-containing proteoliposomes for 1 h at 4°C. After that, unbound material was washed away and fixed with 3.7% (v/v) formaldehyde (A). Otherwise, cells were further incubated for 15 min (B), 2 h (C) or 5 h (D) at 37°C. After fixation, cells were analyzed by fluorescence microscopy. Objective magnification: for (A) 63x; for (B), (C), (D) 100x.

15

EXAMPLES

EXAMPLE 1 - Materials and Methods

Chemicals: Octaethyleneglycol-mono-(n-dodecyl)ether (OEG, C₁₂E₈) and didodecyldimethylammonium bromide (DDAB) were from Fluka, poly-L-lysine hydrobromide (MW 29'300), protamine sulfate, α-cellulose, microcrystalline cellulose and 1,2-Dipalmitoyl-sn-glycero-3-phospho-rac-(1-glycerol) (PG) were purchased from Sigma (Buchs, Switzerland). Egg phosphatidyl choline (PC) was obtained from Lipoid (Cham, Switzerland).

Phosphatidylethanolamine (PE) was obtained from R. Berchtold (Biochemical Laboratory, University of Bern, Switzerland). Bio-beads SM2 and Bio-Gel A-15m were from Bio-Rad Laboratories (Glattbrugg, Switzerland). POPC, N-NBD-PE and N-Rh-PE were from Avanti Polar Lipids (Birmingham, AL, USA). Pancreatic DNase I (from bovine pancreas) with a specific activity of 2000 Kunitz units/mg and exonuclease III (*E. coli* with 100 units/μl) were purchased from Roche Diagnostics

30

(Basel, Switzerland) and New England BioLabs (BioConcept, Allschwil, Switzerland). *Taq* DNA polymerase was from Promega (Catalys, Wallisellen, Switzerland). N-(4,4-difluoro-5,7-diphenyl-4-bora-3a,4a-diaza-s-indacene-3-propionyl)-1,2-dihexadecanoyl-*sn*-glycero-3-phosphoethanolamine (Bodipy 530/550-DHPE), ethidium monoazide bromide (EMA), Texas red-dextran (MW 70'000) and PicoGreen reagent were from Molecular Probes Europe (Leiden, The Netherlands). The oligonucleotides used for the polymerase chain reaction and for the antisense experiments were from Microsynth (Balgach, Switzerland). The plasmids pT7-EGFP, VR1012, EGFP-VR1012 and ³⁵S-labelled plasmid were a kind gift of Karin Moelling (Institute of Medical Virology, University of Zurich, Switzerland).

15 Viruses: Influenza viruses of the X-31 recombinant strain and the A/PR/8/34 (PR8) strain, propagated in the allantoic cavity of embryonated eggs (Gerhard, J. Exp. Med. 144: 985-995, 1976), were obtained from Berna Biotech (Bern, Switzerland). The recombinant vaccinia virus vTF7-3 was a kind gift of Karin Moelling (Institute of Medical Virology, University of Zurich, Switzerland).

Cell culture: MDCK and HeLa cells were maintained in MEM (Life Technologies, Basel, Switzerland) supplemented with 10% FCS, penicillin (100 IU/ml) and streptomycin (100 µg/ml).

EXAMPLE 2

Preparation of immunopotentiating reconstituted influenza virosomes (IRIV): Virosomes were prepared by the method described by Bron and coworkers (Bron et al., Methods Enzymol. 220: 313-331, 1993). Briefly, virus (1.5 µmol of phospholipid or 5 mg of viral protein) was sedimented by ultracentrifugation and solubilized in 0.7 ml of 100 mM OEG in phosphate-buffered saline (PBS, 150 mM NaCl, 5 mM Na-phosphate, pH 7.4). The nucleocapsid was removed by

ultracentrifugation (100'000xg, 30 min). The supernatant (containing the viral lipids and the envelope proteins) was shaken (1200 rpm) with 180 mg of wet Bio-Beads SM2 for 1 h at room temperature and twice for 10 min with 90 mg of Bio-Beads
5 at 1400 rpm to remove the detergent.

Subsequently, the virosome preparation was centrifuged on a 10-40% (w/v) discontinuous sucrose density gradient in PBS at 130'000xg for 90 min. The virosomes were collected from the
10 interface between the sucrose layers.

Chimeric virosomes containing HAs from X-31 and PR8 were prepared similarly. Equal amounts of viral proteins from the two virus strains were mixed before solubilization.
15

The hemagglutinin/phospholipid ratio was determined by phospholipid determination after Böttcher (Böttcher *et al.*, Anal. Chim. Acta 24: 202-203, 1961) and HA-quantification after SDS-PAGE with the Coomassie-extraction method after
20 Ball (Ball, Anal. Biochem. 155: 23-27, 1986).

EXAMPLE 3

Preparation of conventional IRIV with encapsulated molecules: IRIV were basically prepared as described by Zurbriggen *et al.* (Zurbriggen *et al.*, Prog. Lipid Res. 39:3-18, 2000).
25 Briefly, 32 mg egg PC and 8 mg PE were dissolved in 2 ml of PBS containing 100 mM OEG (PBS/OEG). Influenza A/Singapore was purified as described (Skehel and Schild, Virology 44:396-408, 1971). Influenza virus corresponding to 4 mg
30 hemagglutinin (HA) was centrifuged at 100,000 x g for 30 min and the pellet was dissolved in 1 ml of PBS/OEG. To prepare peptide-IRIV, 4 mg of peptide was dissolved in 1 ml PBS/OEG. The phospholipids, the dissolved virus solution and the peptide solution were mixed and sonicated for 1 min. This

mixture was centrifuged at 100,000 x g for 1 h and the supernatant sterile filtered (0.22 µm). Virosomes were then formed by detergent removal using 180 mg of wet SM2 Bio-Beads* for 1 h at room temperature with shaking and three times for 5 30 min with 90 mg of SM2 Bio-Beads*. Size determination of IRIV was done by light scattering using a Zetasizer*1000HS instrument (Malvern Instruments, UK). For quantification of encapsulated peptide, a fraction of the homogenous IRIV were loaded on a Sephadex* G50 Coarse (Amersham Biosciences, 10 Switzerland) gel-filtration column and separated from non-encapsulated peptide. Peptide quantification was done on an Äkta Explorer*10 (Amersham Biosciences, Switzerland) using a CC 125/4.6 Nucleosil 100-5 C8 reverse-phase column (Macherey-Nagel, Switzerland).

15

To prepare protein-IRIV (e.g. GFP-IRIV), 10 µg of protein was dissolved in 1 ml PBS/OEG and continued as described above. To prepare PicoGreen-IRIV, 20 µl of the stock solution was dissolved in 1 ml PBS/OEG and continued as described above. 20 GFP and PicoGreen quantification were done on a LS 55 Luminescence spectrometer (Perkin Elmer Instruments, USA).

Chimeric virosomes containing HAs from Influenza X-31 and Influenza A/Singapore were prepared, but the peptide solution 25 was replaced by 1 ml of OEG/PBS. Equal amounts of HA protein from the two virus strains were mixed before solubilization.

EXAMPLE 4

Preparation of large unilamellar vesicles (LUVs): Twelve 30 milligrams of POPC/DDAB (98:2, molar ratio) were dissolved in chloroform/methanol. Subsequently, the solvent was removed by evaporation, followed by an overnight drying at 10⁻² mm Hg. The dried lipid mixture was dispersed in 50 µl Tris buffer (50 mM Tris, pH 8.0) and sonicated for 15 min in a bath 35 sonicator. Following addition of the substance to be

* - Trademark

encapsulated the concentration of lipids was adjusted to 120-160 mM. The dispersion was frozen in liquid nitrogen and thawed at room temperature ten times. Before extrusion, the liposome dispersion was diluted with Tris buffer to a lipid
5 concentration of 40 mM and extruded ten times each through 0.2 μ m and 0.1 μ m polycarbonate membranes (Nuclepore Track-Etch Membrane, Sterico, Switzerland) with a home made extruder (similar to the LiposoFast from Avestin Inc.).

10 Plasmid DNA was, in principle, encapsulated as described by Monnard and co-workers (Monnard *et al.*, Biochim. Biophys. Acta 1329: 39-50, 1997). To the sonicated liposomes 10 μ g of DNA (for some experiments containing also 35 S-labeled plasmid-DNA) were added and treated as described above. Non-
15 entrapped DNA was digested by adding 700-800 units of pancreatic DNase I, 200 units of exonuclease III, 5 mM MgCl_2 and 0.1 mM DTT to the DNA-containing liposomes (for experiments with higher quantities of DNA the amount of enzymes was proportionally adjusted). After incubating for 3
20 h at 37°C, the reaction was stopped by adding EDTA to final concentration of 7 mM. The external bulk medium was separated from the liposomes by gel filtration spin column chromatography (Bio-Gel A-15m, previously equilibrated with Tris-HCl buffer, pH 8.0). Usually, the columns were
25 centrifuged at 165xg for 2 min. Ten to fifteen fractions of about 50 μ l each were collected. The fractions 2-7 were usually turbid, (the others showed no visible turbidity, indicating that they contained no significant amount of liposomes).

30

Quantification of entrapped DNA into LUVs: To determine the fraction of entrapped plasmid-DNA, 35 S-labeled DNA was co-entrapped into liposomes. From the amount of radioactivity initially added and the quantity of radioactivity still
35 associated with liposomes after extensive DNase I/Exonuclease

III digestion and gel filtration chromatography, the proportion of entrapped DNA could be determined by liquid scintillation counting.

5 Quantification was also performed by visualization of the plasmid-DNA on 1% agarose gels before and after digestion. For these experiments plasmid-DNA of untreated liposomes or of liposomes that were DNase I/exonuclease III digested and gel filtration purified was phenol/chloroform extracted. The
10 aqueous solution containing the DNA was subjected to gel electrophoresis. The gel was stained with ethidium bromide and the bands corresponding to plasmid-DNA quantified visually on the basis of known amounts of plasmid.

15 EXAMPLE 5

Preparation of large unilamellar vesicles (LUVs): 36.4 μmol (27.95 mg) PC and 15.6 μmol (10.75 mg) PG (molar ratio 70:30) were dissolved in methanol/chloroform (2:1). The solvent was removed by using a rotary evaporator (Rotavapor R-205, Büchi
20 Labortechnik, Switzerland) at 40°C at a gradual vacuum of 30-10 kPa. For peptide-liposomes with hydrophobic peptides, 2-3.5 mg peptid was dissolved in methanol and added to the phospholipid mixture before solvent removal. The dried lipid film was hydrated with 500 μl PBS. For peptide-liposomes with
25 hydrophilic peptides, the dried lipid film was hydrated with 350 μl PBS containing 2-3.5 mg peptide to be encapsulated. For GFP-liposomes, the dried lipid film was hydrated with 350 μl PBS containing 10 μg GFP. For PicoGreen-liposomes, the dried lipid film was hydrated with 350 μl PBS containing 1.75
30 μl PicoGreen stock solution. Before extrusion, the volume was adjusted to 500 μl with PBS. The liposome dispersion was extruded ten times through polycarbonate membranes (Nucleopore Track-Etch membrane, 0.1 μm or 0.2 μm , respectively, Whatman, UK) with a 1.5 ml Lipex Extruder*
35 (Northern Lipids, Canada). Size determination of extruded

* - Trademark

liposomes was done by light scattering using a Zetasizer 1000HS instrument (Malvern Instruments, UK). For quantification of encapsulated peptide, a fraction of the homogenous liposomes were loaded on a Sephadex G50 Coarse (Amersham Biosciences, Switzerland) gel-filtration column and separated from non-encapsulated peptide. Peptide quantification was done on an Äkta Explorer 10 (Amersham Biosciences, Switzerland) using a CC 125/4.6 Nucleosil 100-5 C8 reverse-phase column (Macherey-Nagel, Switzerland). GFP and PicoGreen quantification were done on a LS 55 Luminescence spectrometer (Perkin Elmer Instruments, USA).

EXAMPLE 6

Preparation of chimeric proteoliposomes: Chimeric virosomes (50 µl) were incubated with 2 µl of POPC/DDAB LUVs at 4°C in PBS (final volume 200 µl) adjusted to pH 5.0 with 5 µl of citric acid (150 mM, adjusted to pH 3.5). After neutralization with 1.4 µl of 1 M NaOH, fusion products were extruded ten times through 0.2 µm polycarbonate membranes. Fused proteoliposomes were prepared freshly for each experiment, since it was noted that they are prone to aggregation.

In order to analyze whether extrusion leads to loss of DNA, liposomes containing ³⁵S-labeled DNA were fused with chimeric virosomes and extruded as described above. Proteoliposomes were then digested with DNase I and Exonuclease III as already described above. The fraction of radioactivity associated with proteoliposomes after gel filtration chromatography was determined by liquid scintillation counting. Control probes were treated the same except that they were either not extruded or extruded but not digested.

Fusion measurements by FRET: For *in vitro* fusion experiments 0.6% each of N-NBD-PE and N-Rh-PE were incorporated into LUVs

consisting of POPC/DDAB (98:2) (1 mg/ml). Fluorescence measurements were carried out at 4°C and 37°C in a final volume of 2 ml PBS (5 mM Na-phosphate, pH 7.4 and 150 mM NaCl). Liposomes (19 µl) and 30-50 µl of virosomes were present in the cuvette. After addition of 48 µl of citric acid (150 mM, adjusted to pH 3.5 with NaOH) an increase in fluorescence was recorded continuously at excitation and emission wavelengths of 465 nm and 530 nm, respectively. Measurements were carried out with a SPEX Fluorolog-2* fluorometer (SPEX Industries, Edison, NJ, USA) equipped with a thermostated cuvette holder and a magnetic stirring device. For calibration of the fluorescence scale the initial residual fluorescence of the liposomes was set to zero and the fluorescence at infinite probe dilution determined after the addition of Triton*X-100 (0.5% v/v final conc.) to 100%.

Cryo transmission electron microscopy (Cryo-TEM): Small drops of a virosome- or liposome-containing dispersion were applied to carbon-coated copper grids and frozen immediately in liquid ethane in a controlled environment vitrification system (Egelhaaf et al., J. Microsc. 200: 128-139, 2000). Vitrified specimens were transferred using a modified cryoholder (Gatan, Pleasanton, CA, USA) into a transmission electron microscope (Zeiss EM 912 OMEGA) operated at 120 keV and 'zero loss' conditions. After an equilibration time of 5 min the specimens were examined at -170°C. Electron micrographs were digitally recorded without flat field correction using a cooled 1024x1024 CCD camera (Proscan, Germering, Germany) controlled by a SYS image analysis system version 2.1 (SYS, Münster, Germany).

EXAMPLE 7

Preparation of chimeric proteoliposomes: Chimeric virosomes (600 µl in PBS) were incubated with 200 µl of PC/PG LUVs at 15°C in PBS under constant stirring. To trigger the fusion

* - Trademark

the pH was adjusted to about 4.5 with 15 μ l of 1 M HCl. After incubation for 30 min, the mixture was neutralized with 15 μ l of 1 M NaOH and fusion products were extruded ten times through 0.2 μ m polycarbonate membranes as described in example 4. For *in vitro* fusion measurements by FRET, an alternative assay was developed: 0.75 mol% of Bodipy530/550-DHPE and 0.25 mol% of Rh-DHPE were incorporated into LUVs consisting of PC/PG (70:30). Bodipy530/550-DHPE is advantageous over N-NBD-PE since its extinction coefficient is three times higher and less sensitive to the solvent. Fluorescence measurements were carried out at distinct temperatures between 4°C and 42°C in 5 mM sodium phosphate buffer pH 7.5, 100 mM NaCl, in a final volume of 0.8 ml in 2.5 ml PMMA micro-cuvettes (VWR, Switzerland) under continuous stirring. Typically, 1 μ l of labeled liposomes (0.3 μ mol phospholipid) were mixed with 5-50 μ l of virosomes and fusion was triggered by addition of 3.75-7 μ l of 1 M HCl, resulting in a pH around 4.5. The increase in fluorescence was recorded continuously at excitation and emission wavelengths of 530 nm and 550 nm, respectively, with an excitation slit of 2.5 nm and an emission slit of 15.0 nm. Measurements were carried out with a LS 55 Luminescence spectrometer (Perkin Elmer Instruments, USA) equipped with a thermostated cuvette holder and a magnetic stirring device. The maximal fluorescence at infinite probe dilution was reached after addition of Triton X-100 (0.5% v/v final concentration).

EXAMPLE 8

Transfection experiments: MDCK or HeLa cells (1×10^5) were seeded on 24 well plates the day before transfection and transfected with 1 μ g of plasmid DNA (EGFP-VR1012) per well, using SuperFect reagent according to the manufacturer's protocol (Qiagen, Basel, Switzerland).

Preparation of rhodamine-labeled chimeric proteoliposomes:
One milligram of lipids (POPC/DDAB/N-Rh-PE 98:2:0.5) were
dissolved in chloroform/methanol. Subsequently the solvent
was removed by evaporation followed by overnight drying at
5 10-2 mm Hg. The dried lipids were dispersed in 200 µl PBS.
The dispersion was frozen in liquid nitrogen and thawed at
room temperature ten times. After that, liposomes were
extruded ten times through each 0.2 µm and 0.1 µm
polycarbonate membranes.

10

Rhodamine-labeled proteoliposomes were prepared from 50 µl of
rhodamine-LUVs and 100 µl of chimeric virosomes in a total
volume of 200 µl as described above. Briefly, the dispersion
was acidified and incubated for 10 min at 4°C. Following
15 neutralisation with 1 M NaOH, proteoliposomes were extruded
ten times through a 0.2 µm polycarbonate membrane.

For transfection with DNA-containing proteoliposomes the same
number of cells was seeded. Chimeric proteoliposomes (10-20
20 µl) containing the EGFP-VR1012 plasmid were incubated with
the cells in 200 µl medium (MEM or MEM supplemented with 10%
FCS, or RPMI containing 0.2% BSA) at 4°C for 1 h or at 37°C
for 2.5-4 h before removing the medium. The cells were then
incubated in total growth medium at 5% CO₂ and 37°C for 48-70
25 h.

Transfected cells were examined for EGFP expression using a
Zeiss Axiovert wide-field microscope.

30 EXAMPLE 9

Cellular uptake studies of rhodamine-labeled proteoliposomes:
MDCK or HeLa cells (1×10^5) were grown to 60-80% confluency on
12 mm Alcian blue-coated coverslips and incubated with 10 µl
of rhodamine-labeled proteoliposomes in 100 µl RPMI-medium
35 supplemented with 20 mM HEPES and 0.2% BSA for 1 h at 4°C

protected from light. Cells were then washed extensively with ice-cold PBS and incubated in total growth medium (MEM, 10% FCS) at 5% CO₂ and 37°C. At the indicated time points, cells were fixed with 3.7% (v/v) formaldehyde. Coverslips were
5 mounted in Moviol and examined using a Zeiss Axiovert wide-field microscope. Images were collected using a CCD camera (Hamamatsu) and standard filters.

Cellular localization studies of ethidium monoazide
10 bromide(EMA)-labeled DNA: EMA-labeled plasmid DNA was essentially prepared as described (Zabner et al., J. Biol. Chem. 270: 18997-19007, 1995; Serikawa et al., Biochim. Biophys. Acta 1467: 419-430, 2000). To 200 µg EGFP-VR1012 in 100 µl of H₂O were added 5 µg of EMA (5 mg/ml in EtOH). After
15 a 15 min incubation period on ice, the solution was photoactivated (SUSS LH 1000 lamphouse (KARL SUSS, Waterbury Center, VT, USA) equipped with an OSRAM HBO 350 W high pressure mercury lamp) for 10 min. To remove free reagent, the DNA was precipitated three times with 3 volumes of
20 ethanol and 0.1 volumes of 3 M sodium acetate (pH 5.2). Labeled DNA was resuspended in 70-100 µl of H₂O.

EMA-labeled DNA was then either encapsulated into LUVs and used for transfection experiments with proteoliposomes or
25 prepared with SuperFect as described above. For intracellular localization studies of EMA-labeled DNA a Zeiss Axiovert wide-field microscope was used.

Cellular uptake studies of proteoliposomes containing Texas
30 red-dextran: To 6 mg of dried lipids (POPC/DDAB 98:2) in 50 µl Tris-HCl buffer (50 mM Tris-HCl, pH 8.0) were added 3 mg of Texas red-dextran (70'000 MW) in 30 µl Tris buffer. Liposomes were prepared as described above. Free dextran was separated from liposomes by a sucrose density gradient.
35 Briefly, 100 µl of the extruded liposomes were mixed with 900

5 μ l of 60% sucrose in Tris-HCl buffer, then 1 ml each of 30%, 20% and 10% sucrose were layered on top. The final layer consisted of 500 μ l Tris-HCl buffer. Gradients were centrifuged for 3 h at 35'000 rpm and 20°C in a SW 55 Rotor (Beckman). Dextran-containing liposomes could be collected as a fine band in the upper regions of the gradient. The collected fraction was diluted with Tris buffer and concentrated to ca. 200 μ l with an ultrafree centrifugal filter device (Millipore, Volketswil, Switzerland).

10

Texas red-dextran-containing liposomes were fused with chimeric virosomes in the cold as described above. The fusion products were incubated with cells as already described. Uptake and release of Texas red-dextran into the cytosol was
15 analyzed by fluorescence microscopy with a Zeiss Axiovert wide-field microscope after fixation of cells.

EXAMPLE 10

Transfection experiments using the T7-cytoplasmic expression
20 system: HeLa cells (3×10^5) grown on coverslips were infected with vTF7-3 (MOI of 5). After 1 h the incubation medium was removed, and the cells were transfected with proteoliposomes containing pT7-EGFP or with lipofectamin according to the manufacturer's protocol (Invitrogen AG, Basel, Switzerland).
25 The medium was replaced 4 h after transfection, and the cells were incubated for an additional 40-60 h before analysis for GFP expression by fluorescence microscopy.

Plasmid isolation from transfected cells and amplification by
30 polymerase chain reaction: MDCK and HeLa cells were grown to 60-80% confluency on 60 mm plates. EGFP-VR1012 encapsulated in proteoliposomes or as Superfect-complexes was added to cells as described. After different incubation times at 37°C cells were lysed and plasmid isolated by Hirt extraction
35 (Hirt, J. Mol. Biol. 26: 365-369, 1967). Briefly, 0.4 ml of a

0.6% (w/v) SDS, 10 mM EDTA solution were added to each plate, and incubated for 20 min at room temperature. Cells were scraped off with a rubber policeman. The viscous mixture was pipetted into an Eppendorf tube, 100 µl of a 5 M NaCl solution were added, and the mixture was chilled on ice for at least 5 h. After centrifuging for 4 min at 14'000 rpm at 4°C, the supernatant was carefully removed and extracted twice with phenol and once with chloroform. The aqueous phase was precipitated with 3 volumes of ethanol and 0.1 volumes of 3 M sodium acetate (pH 5.2) overnight at -20°C. The pellet was washed with 70% ethanol and resuspended in 20 µl of H₂O.

For the polymerase chain reaction (PCR) the following reagents were assembled in a total volume of 20 µl:

15 1-2 µl isolated plasmid DNA
 1x Taq DNA polymerase buffer
 1.5-2 mM MgCl₂
 20 µM dNTPs (5 µM each)
 1 µM of each primer
20 1 U Taq DNA polymerase

The primers used were:

VR1012-for: 5'-GCCACCAGACATAATAGCTG-3'

EGFP-rev: 5'-GGCTGTTGTAGTTGTACTCC-3'

25

Cycling parameters:

1 cycle 94°C 45 s

19-24 cycles 94°C 45 s

 52°C 45 s

30

 72°C 45 s

1 cycle 72°C 10 min

The products were then analyzed on a 8% (v/v) polyacrylamide gel with a thickness of 1 mm.

35

Gel protocol:

1 ml 40% (v/v) acrylamide

1 ml 5x TBE

2.625 ml H₂O

5 375 µl Glycerol

30 µl 10% (w/v) APS

6 µl TEMED

Condensation of DNA with poly-L-lysine or protaminesulfate:

10 DNA-poly-lysine/DNA-protamine complexes were prepared by the slow addition of varying amounts of polycation (12.5 -100 µg) to 50 µg of plasmid DNA and 2.5 µmol of lipids (POPC/DDAB 98:2) in total 0.5 ml of H₂O or PBS.

15 EXAMPLE 11

Antisense-Experiments: Preparation of proteoliposomes containing c-myc oligodeoxynucleotides: One hundred microliters of a 15 mM c-myc oligodeoxynucleotide-stock solution (final 1.5 µmol) were added to the sonicated lipid dispersion and treated as described for the preparation of LUVs. Not encapsulated oligodeoxynucleotides were removed by gel filtration as described for encapsulation of plasmid DNA (without digestion). The first four eluates containing liposomes were pooled and concentrated with an ultrafree centrifugal filter device (Millipore, Volketswil, Switzerland) to the original volume (50 µl).

Sequences of oligodeoxynucleotides (phosphorothioated) used:

antisense: 5'-AACGTTGAGGGGCAT-3'

scrambled: 5'-GAACGGAGACGGTTT-3'

30 Oligodeoxynucleotides-containing LUVs were fused with chimeric virosomes and subsequently extruded.

Encapsulation of c-myc oligodeoxynucleotides into PR8-virosomes: To encapsulate c-myc oligodeoxynucleotides directly into PR8-virosomes, 1.5 µmol oligodeoxynucleotides

in 100 μ l of H₂O were added to the solubilized viral fraction. PR8-virosomes were then prepared as described above.

- 5 Cellular delivery of oligodeoxynucleotides: HeLa cells (4×10^3 per well) were seeded the day before transfection in a 96 well plate. For transfections with oligofectamine (Invitrogen AG, Basel, Switzerland) cells were kept in growing medium without penicillin/streptomycin. Cells were
10 treated with c-myc antisense and scrambled phosphorothioated oligonucleotides complexed with oligofectamine according to the manufacturer's protocol.

For transfections with ODN-containing proteoliposomes 2-3 μ l
15 of fused virosomes were incubated with cells in total 100 μ l of medium (RPMI with 0.2% BSA or MEM or MEM with 10% FCS) at 37°C and 5% CO₂ for three days. For some experiments proteoliposomes were first incubated at 4°C for 1 h. Unbound particles were washed away, growing medium was added and
20 incubated at 37°C as described. Cell proliferation was tested after 70 h with the "CellTiter 96Aqueous one Solution Cell Proliferation Assay" as described by the manufacturer (Promega (Catalys, Switzerland). After addition of 20 μ l of reagent per well and a 1 to 3 hours-incubation at 37°C and 5%
25 CO₂, absorbance was recorded at 450 nm using a Benchmark microplate reader (Bio- Rad Laboratories, Glattbrugg, Switzerland).

Cellular uptake studies of FITC-labeled
30 oligodeoxynucleotides: HeLa cells (1×10^5) seeded on 12 mm coverslips were treated with oligofectamin and FITC-labeled oligodeoxynucleotides as described above.

The same number of cells was seeded for treatment with
35 chimeric proteoliposomes or PR8-virosomes. 20 μ l of

proteoliposomes or 10 μ l of PR8- virosomes containing FITC-labeled oligodeoxynucleotides were incubated with cells in 200 μ l of medium (RPMI containing 0.2% BSA) at 4°C for 1 h. Medium was then removed and cells were incubated in total
5 growth medium at 5% CO₂ and 37°C.

At the indicated time points cells were fixed with 3.7% (v/v) formaldehyde. Coverslips were mounted in Moviol and examined using a Zeiss Axiovert wide-field microscope. Images were
10 collected using a CCD camera (Hamamatsu) and a standard FITC-filter.

EXAMPLE 12

Fusion experiments with erythrocytes: Freshly washed chicken
15 erythrocytes (0.8%) were received from Berna Biotech (Bern, Switzerland) in PBS⁺ (7 mM Na₂HPO₄, 5 mM KH₂PO₄, 138 mM NaCl, 3 mM KCl and 1 mM MgCl₂, pH 7.2).

Before each experiment, erythrocytes were centrifuged for 5
20 min at 830xg and resuspended in PBS (150 mM NaCl, 5 mM Na-phosphate, pH 7.4) or in ddH₂O to the same volume (500 μ l). Different amounts of virus (1-20 μ g protein) and corresponding amounts of virosomes (PR8, X-31), chimeric virosomes and proteoliposomes were added and incubated for 15
25 min at 37°C under gentle shaking at pH 5.0, pH 5.5, pH 6.0 and pH 7.3, respectively. Subsequently the samples were neutralized with 1 M NaOH. Erythrocytes were sedimented for 5 min at 830xg. The absorbance of the supernatant was measured at 541 nm to determine the hemolytic activity. The percentage
30 hemolysis was measured by $100 \times (A - A_0) / (A_{100} - A_0)$, where A_{100} was the absorbance for 100% hemolysis determined for erythrocytes in distilled water and A_0 was the base line absorbance measured in the absence of virus/virosomes.

The cell pellet was resuspended in 500 μ l PBS. Drops of the suspension were added to a coverslip and prepared for light microscopy.

- 5 To inactivate chimeric virosomes, 50 μ l of virosomes were incubated in a total volume of 200 μ l at 37°C. Following acidification with 5 μ l of citric acid (150 mM, pH 3.5), the suspension was incubated for another 30 min at 37°C and reneutralized with 1.4 μ l of 1 M NaOH. Twenty microliter of
10 this mixture were used per hemolysis reaction.

Photolabeling experiments: Biotinyl-TID-PE/16 containing PR8-virosomes were prepared as described above, with the exception that after the solubilization step with $C_{12}E_8$ 300
15 nmols (10% of the viral phospholipids) of dried biotinyl-TID-PE/16 were added.

For the preparation of biotinyl-TID-PE/16 containing proteoliposomes LUVs prepared from POPC/DDAB/biotinyl-TID-
20 PE/16 (98:2:20) (5 mg/ml) were fused with chimeric virosomes. Biotinyl-TID-PE/16-LUVs (20 μ l) were incubated with 50 μ l of chimeric virosomes in a total volume of 200 μ l at pH 5.0 and 4°C for 10 min. Subsequently, the mixture was neutralized and proteoliposomes extruded ten times through 200 nm pores.

25 Preparation of ghosts from human erythrocytes: Fresh human blood was obtained from the Stiftung Zurcher Blutspendedienst (SRK), Blutspendezentrum Zurich (Switzerland). In order to isolate red blood cells 20 ml of blood were filtered through
30 a bed of α -cellulose and microcrystalline cellulose (1 g each) in PBS (138 mM NaCl, 10 mM Na-phosphate, pH 7.3) as previously described by Beutler (Beutler et al., J. Lab. Clin. Med. 88: 328-333, 1976). The filtrate was washed 4
35 times by sedimenting cells in a SS-34 rotor (Sorvall) at 2500 rpm and 4°C for 7 minutes and resuspending the cells in PBS.

After the final wash cells were resuspended in 20 ml PBS and prepared (as described by the manufacturer) for counting on a Sysmex Microcellcounter F-800 (TOA Medical Electronics, Inc., Hamburg, Germany).

5

Ghosts were essentially prepared as described by Steck (Steck and Kant, Methods Enzymol. 31: 172-180, 1974).

10 Packed erythrocytes (1 ml) were mixed with 40 ml of hemolysis buffer (5 mM phosphate, pH 7.4, 1 mM EDTA, 15 µg/ml PMSF). Ghosts were pelleted by centrifugation at 22'000xg for 10 min. The supernatant and a small, hard button, rich in contaminating proteases, were carefully aspirated. Membranes were resuspended in hemolysis buffer and washed three more
15 times until they were creamy white. Finally, ghosts were resuspended in 1 ml of hemolysis buffer.

Photolabeling experiments: Biotinyl-TID-PE/16 containing PR8-virosomes were prepared as described previously, with the
20 exception that after the solubilization step with C₁₂E₈ 300 nmols (10% of the viral phospholipids) of dried biotinyl-TID-PE/16 were added. For the preparation of biotinyl-TID-PE/16 containing proteoliposomes LUVs prepared from POPC/DDAB/biotinyl-TID-PE/16 (98:2:20) (5 mg/ml) were fused
25 with chimeric virosomes. Biotinyl-TID-PE/16-LUVs (20 µl) were incubated in 50 µl of chimeric virosomes in a total volume of 200 µl at pH 5.0 and 4°C for 10 min. Subsequently, the mixture was neutralized and proteoliposomes extruded ten times through 200 nm pores. Biotinyl-TID-PE/16-
30 proteoliposomes (20 µl) or 5 µl of biotinyl-TID-PE/16-PR8-virosomes were incubated with 20 µl of ghosts in a total volume of 50 µl at 37°C for 20 min. The low pH probes were incubated at the mentioned conditions after acidification with citrate buffer to pH 5.0. After reneutralization with 1
35 M NaOH, respective samples were photolysed for 90 s by

placing them approx. 10 cm from a SUSS LH 1000 lamphouse
(KARL SUSS, Waterbury Center, VT) equipped with an OSRAM HBO
350 Watt short-arc high pressure mercury lamp. Protein was
precipitated with 3 volumes of chloroform/methanol 1:2 to
5 remove unbound label. After that, samples were prepared for
separation on a SDS 8% (v/v) polyacrylamide gel by
electrophoresis.

Detection of biotinylated proteins was performed by western-
10 blotting: Proteins separated by SDS-PAGE were transferred
electrophoretically onto an Immobilon-P PVDF membrane
(Millipore, Volketswil, Switzerland). The gel was blotted for
2 h at 110 mA in a transfer buffer containing 20% methanol,
20 mM Tris-HCl, 200 mM glycine. The blotting efficiency was
15 checked by using the Kaleidoscope prestained protein standard
(Bio-Rad Laboratories, Glattbrugg, Switzerland) and by
staining the blotted gel with Coomassie blue.

The blot was blocked for a minimum of 1 hour with TBS-T (137
20 mM NaCl, 20 mM Tris-HCl, 0.1% (v/v) Tween 20, pH 7.6)
containing 5% BSA at room temperature. The primary antibody
(α biotin, Bethyl laboratories, Montgomery, TX, USA) diluted
1:1000 in TBS-T containing 5% BSA was added and allowed to
bind for 1 hour. The membrane was washed for 15 min with TBS-
25 T, followed by two short (5 min) wash steps with TBS-T and
one with TBS (137 mM NaCl, 20 mM Tris-HCl, pH 7.6). The
second antibody (goat α -rabbit Horseradish peroxidase-
conjugated, Pierce (Socochim, Lausanne, Switzerland)) diluted
1:20,000 in TBS-T containing 5% BSA was added and allowed to
30 bind for 1 hour at room temperature. The membrane was again
extensively washed as described above.

The wet blot was developed using the ECL⁺Plus detection
solution (Amersham Biosciences, Dubendorf, Switzerland) as
35 described by the manufacturer.

Hemolysis and cell-cell fusion with human erythrocytes:
Hemolysis and cell-cell fusion experiments with human
erythrocytes were performed as described above for chicken
5 erythrocytes. Per sample 6×10^7 washed red blood cells were
used.

SEQUENCE LISTING

<110> Pevion Biotech Ltd.
 <120> High-efficiency fusogenic vesicles, methods of producing them,
 and pharmaceutical compositions containing them
 <130> 69503/2
 <140> Canadian Patent Application No. 2,506,593
 <141> 2003-11-19
 <150> US 60/428,435
 <151> 2002-11-21
 <160> 4
 <170> PatentIn version 3.3
 <210> 1
 <211> 20
 <212> DNA
 <213> Artificial
 <220>
 <223> PCR Primer VR1012-for
 <400> 1
 gccaccagac ataatagctg 20
 <210> 2
 <211> 20
 <212> DNA
 <213> Artificial
 <220>
 <223> PCR Primer EGFP-rev
 <400> 2
 ggctgttgta gttgtactcc 20
 <210> 3
 <211> 15
 <212> DNA
 <213> Artificial
 <220>
 <223> antisense c-myc oligodeoxynucleotide (phosphorothioated)
 <400> 3
 aacgttgagg ggcac 15
 <210> 4
 <211> 15
 <212> DNA
 <213> Artificial
 <220>
 <223> scrambled antisense c-myc oligodeoxynucleotide
 (phosphorothioated)

<400> 4
gaacggagac ggttt

15

We Claim:

1. A unilamellar fusogenic vesicle, composed of virosomal and liposomal lipids, encapsulating at least one therapeutic or immunologically active substance, said fusogenic vesicle comprising fusion proteins with distinct fusion characteristics, said fusion proteins coming from different virus strains.
2. The fusogenic vesicle according to claim 1, wherein the encapsulated therapeutic or immunologically active substance is selected from the group comprising:
 - DNA, RNA, siRNA, proteins, peptides, amino acids; or
 - a cosmetic agent, a pharmaceutical drug, an antigen or mixtures thereof;
 - wherein the cosmetic agent is selected from the group consisting of antipsoriatics and antifungals for dermatological use; and
 - wherein the pharmaceutical drug is selected from the group consisting of anaesthetics, angiogenesis inhibitors, anti-acne preparations, anti-allergics, antibiotics, chemotherapeutics for topical use, antihistamines, antiinflammatory/antiinfectives, antineoplastic agents, antiprotozoals, antirheumatics, antiviral vaccines, antivirals, bacterial vaccines, chemotherapeutics, cytostatics, immunosuppressive agents, laxatives and psycholeptics.
3. The fusogenic vesicle according to claim 2 wherein the cosmetic agent is tars nystatin.
4. The fusogenic vesicle according to claim 2 wherein the pharmaceutical drug is doxorubicin, vinblastine, cisplatin, methotrexate, cyclosporin, ibuprofen, HCV based T-cell antigens and tumor associated antigens.
5. The fusogenic vesicle according to any one of claims 1-4, wherein the distinct fusion characteristics are selected from temperature, ion concentration, acidity, cell type and tissue type specificity.
6. The fusogenic vesicle according to claim 5, wherein the distinct fusion characteristics of the fusion proteins are temperature-specific.

7. The fusogenic vesicle according to claim 6, wherein the fusion proteins are derived from the group comprising influenza, vesicular stomatitis virus (VSV), semliki forest virus (SFV), Sendai and human immunodeficiency virus (HIV) viruses.
8. The fusogenic vesicle according to claim 7, wherein the fusion proteins are derived from influenza virus.
9. The fusogenic vesicle according to claim 8, wherein the fusion proteins are X-31 HA, PR8/34 or A/Singapore HA or fragments thereof.
10. The fusogenic vesicle according to any one of the preceding claims, wherein the liposomal lipids are selected from the group comprising glycolipids, phospholipids, cholesterol and cationic lipids selected from the group comprising DOTMA (N-[(1-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride), DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride), DODAC (N,N-dioleoyl-N,N, -dimethylammonium chloride), DDAB (didodecyldimethylammonium bromide) and stearylamine.
11. The fusogenic vesicle according to claim 10, wherein the liposomal lipids comprise 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and didodecyldimethylammonium bromide (DDAB).
12. The fusogenic vesicle according to any one of claims 1-11, wherein the virosomal lipids are derived from the group comprising influenza, VSV, SFV, Sendai and HIV virus.
13. The fusogenic vesicle according to claim 12, wherein the virosomal lipids are derived from influenza virus.
14. The fusogenic vesicle according to any one of claims 1-13, wherein the vesicle has a diameter of between 100 and 300 nm.
15. The fusogenic vesicle according to any one of claims 1-14, further having a cell-surface receptor, cytokine, growth-factor, antibody, or antibody fragment incorporated in the membrane or attached to said membrane.

16. A method for preparing a unilamellar fusogenic vesicle encapsulating at least one therapeutic or immunologically active substance, comprising fusing liposomes encapsulating at least one therapeutic or immunologically active substance with virosomes having fusion proteins with distinct fusion characteristics, said fusion proteins coming from different virus strains.

17. A method of encapsulating at least one therapeutic or immunologically active substance in a unilamellar fusogenic vesicle, comprising fusing liposomes encapsulating at least one therapeutic or immunologically active substance with virosomes having fusion proteins with distinct fusion characteristics, said fusion proteins coming from different virus strains.

18. The method according to any one of claims 16 or 17, wherein the encapsulated at least one therapeutic or immunologically active substance is selected from the group comprising:

- DNA, RNA, siRNA, proteins, peptides, amino acids; or
- a cosmetic agent, a pharmaceutical drug, an antigen or mixtures thereof;
 - wherein the cosmetic agent is selected from the group consisting of antipsoriatics and antifungals for dermatological use; and
 - wherein the pharmaceutical drug is selected from the group consisting of anaesthetics, angiogenesis inhibitors, anti-acne preparations, anti-allergics, antibiotics, chemotherapeutics for topical use, antihistamines, antiinflammatory/antiinfectives, antineoplastic agents, antiprotozoals, antirheumatics, antiviral vaccines, antivirals, bacterial vaccines, chemotherapeutics, cytostatics, immunosuppressive agents, laxatives and psycholeptics.

19. The method according to claim 18 wherein the cosmetic agent is tars nystatin.


20. The method according to claim 18 wherein the pharmaceutical drug is doxorubicin, vinblastine, cisplatin, methotrexate, cyclosporin, ibuprofen, HCV based T-cell antigens and tumor associated antigens.

21. The method according to any one of claims 16 to 20, wherein the distinct fusion characteristics of the fusion proteins are selected from temperature, ion concentration, acidity, cell type and tissue type specificity.



22. The method according to claim 21, wherein the distinct fusion characteristics of the fusion proteins are temperature-specific.
23. The method according to claim 22, wherein fusion proteins are used that are derived from the group comprising influenza, VSV, SFV, Sendai and HIV viruses.
24. The method according to claim 23, wherein the fusion proteins are used that are derived from influenza virus.
25. The method according to claim 24, wherein the fusion proteins are X-31 HA, PR8/34 or A/Singapore HA or fragments thereof.
26. The method according to any one of claims 16 to 25, wherein the liposome is comprised of lipids selected from the group comprising glycolipids, phospholipids, cholesterol, and cationic lipids selected from the group comprising DOTMA (N-[(1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride), DOTAP (N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride), DODAC (N,N-dioleoyl-N,N, -dimethylammonium chloride), DDAB (didodecyldimethylammonium bromide) and stearylamine.
27. The method according to claim 26, wherein the liposome is comprised of POPC and DDAB.
28. The method according to any one of claims 16 to 27, wherein the virosome comprises a fusion protein of a virus selected from the group comprising influenza, VSV, SFV, Sendai and HIV viruses.
29. The method according to claim 28, wherein the virosome comprises a fusion protein derived from influenza virus.
30. The method according to any one of claims 16 to 29, further comprising re-sizing the fusogenic vesicles obtained after fusing liposomes encapsulating at least one therapeutic or immunologically active substance with virosomes having fusion proteins with distinct fusion characteristics.

31. The method according to claim 30, wherein said re-sizing is performed by extrusion of the vesicles.
32. The method according to any one of claims 16 to 31, wherein re-sizing the fusogenic vesicle results in a diameter of between 100 and 300 nm.
33. The method according to any one of the claims 16 to 32, whereby at least one cell-surface receptor, cytokine, growth-factor, antibody, or antibody fragment is attached to the membrane or incorporated in the membrane of the fusogenic vesicle.
34. Use of a fusogenic vesicle as claimed in any one of the claims 1 to 15 for the preparation of a pharmaceutical formulation for the treatment or prevention of viral, bacterial and fungal infections, degenerative diseases, hyper-proliferative diseases, other kinase associated disorders, infectious diseases, chronic infectious diseases, chronic diseases, allergies, cardiovascular diseases, inflammatory diseases, immune diseases, cancer immune disorders, asthma and arthritis.
35. Use of a fusogenic vesicle as claimed in claim 34 wherein the hyper-proliferative diseases and other kinase associated disorders is cancer.
36. Use of a fusogenic vesicle as claimed in claim 34 wherein the inflammatory diseases are skin inflammatory diseases.







1/8

Figure 1

2/8

Figure 2Figure 3

3/8

Figure 4**1 a)****b)****2 a)****b)****3 a)****b)**

4/8





Figure 5**Figure 6**

Figure 7



6/8

Figure 8

7/8





Figure 9

Figure 10



○ : Fusion competent HA

◻ : inactivated HA (resulting from acid-induced conformational change)